Ciluprevir was a drug used experimentally in the treatment of hepatitis C. It is manufactured by Boehringer Ingelheim and developed under the research code of BILN 2061. It was the first-in-class NS3/4A protease inhibitor to enter clinical development and tested in human. Ciluprevir is a potent competitive reversible inhibitor of NS3/4A protease from HCV genotype 1a (Ki = 0.3 nM) and 1b (Ki = 0.66 nM). It shows good selectivity for NS3 protease against representative serine and cysteine proteases, human leukocyte elastase and cathepsin B (IC50 > 30 μM).
Attributes | Values |
---|---|
rdf:type |
|
rdfs:label |
|
rdfs:comment |
|
foaf:depiction | |
dcterms:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage | |
sameAs | |
dbp:wikiPageUsesTemplate | |
thumbnail | |
ATC prefix |
|
c |
|
CAS number |
|
ChEMBL |
|
ChemSpiderID |
|
H |
|
IUPAC name |
|
legal status |
|
n |
|
O |
|
PubChem |
|
routes of administration | |
s |
|
SMILES |
|
StdInChI |
|
StdInChIKey |
|
UNII |
|
width |
|
has abstract |
|
Jmol |
|
protein bound |
|
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
CAS number |
|
ChEMBL |
|
FDA UNII code |
|
PubChem |
|
foaf:isPrimaryTopicOf | |
is Link from a Wikipage to another Wikipage of | |
is Wikipage redirect of | |
is foaf:primaryTopic of |